Compare · AEON vs NVS
AEON vs NVS
Side-by-side comparison of AEON Biopharma Inc. (AEON) and Novartis AG (NVS): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both AEON and NVS operate in Biotechnology: Pharmaceutical Preparations (Health Care), so they compete in similar markets.
- NVS is the larger of the two at $293.40B, about 22530.2x AEON ($13.0M).
- Over the past year, AEON is down 64.3% and NVS is up 34.7% - NVS leads by 98.9 points.
- AEON has hit the wire 7 times in the past 4 weeks while NVS has been quiet.
- NVS has more recent analyst coverage (25 ratings vs 1 for AEON).
- Company
- AEON Biopharma Inc.
- Novartis AG
- Price
- $0.28-1.22%
- $153.72+0.64%
- Market cap
- $13.0M
- $293.40B
- 1M return
- -59.42%
- +1.89%
- 1Y return
- -64.27%
- +34.67%
- Industry
- Biotechnology: Pharmaceutical Preparations
- Biotechnology: Pharmaceutical Preparations
- Exchange
- AMEX
- NYSE
- IPO
- News (4w)
- 7
- 0
- Recent ratings
- 1
- 25
Novartis AG
Novartis AG researches, develops, manufactures, and markets healthcare products worldwide. The company operates through two segments, Innovative Medicines and Sandoz. The Innovative Medicines segment offers prescription medicines for patients and healthcare providers. It also provides ophthalmology, neuroscience, immunology, hepatology and dermatology, respiratory, established, and cardiovascular, renal and metabolism medicine products. The Sandoz segment provides active ingredients and finished dosage forms of small molecule pharmaceuticals to third parties across a range of therapeutic areas, as well as finished dosage form anti-infectives. It also provides active pharmaceutical ingredients and intermediates primarily antibiotics; protein- or other biotechnology-based products, including biosimilars; and biotechnology manufacturing services. Novartis AG has a license and collaboration agreement with Alnylam Pharmaceuticals to develop, manufacture, and commercialize inclisiran; an agreement with CureVac to manufacture COVID-19 vaccine candidate CVnCoV; a collaboration with Artios Pharma Limited to create next generation DDR cancer therapies; and a clinical collaboration with Kura Oncology, Inc. to evaluate the combination of Tipifarnib and Alpelisib in patients with head and neck squamous cell carcinoma. The company was incorporated in 1996 and is headquartered in Basel, Switzerland.
Latest AEON
- AEON Biopharma Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Other Events, Financial Statements and Exhibits
- SEC Form 424B4 filed by AEON Biopharma Inc.
- AEON Biopharma Announces Pricing of Upsized $13.75 Million Public Offering with Accompanying Milestone Warrants Providing Potential for Additional Future Funding
- SEC Form EFFECT filed by AEON Biopharma Inc.
- SEC Form S-1MEF filed by AEON Biopharma Inc.
- Amendment: SEC Form S-1/A filed by AEON Biopharma Inc.
- SEC Form S-1 filed by AEON Biopharma Inc.
- Director Thunen Shelley B was granted 222,684 shares, increasing direct ownership by 618% to 258,705 units (SEC Form 4)
- Director Palmisano Robert J was granted 222,684 shares, increasing direct ownership by 618% to 258,705 units (SEC Form 4)
- Director Forth Marc was granted 222,684 shares, increasing direct ownership by 30% to 973,231 units (SEC Form 4)
Latest NVS
- The Quest to Repair What Multiple Sclerosis Takes Away
- SEC Form 6-K filed by Novartis AG
- SEC Form 6-K filed by Novartis AG
- SEC Form 6-K filed by Novartis AG
- Novartis AG upgraded by Argus with a new price target
- Novartis successfully completes acquisition of Avidity Biosciences, strengthening late-stage neuroscience pipeline and advancing xRNA strategy
- SEC Form S-8 filed by Novartis AG
- SEC Form 6-K filed by Novartis AG
- SEC Form 6-K filed by Novartis AG
- SEC Form IRANNOTICE filed by Novartis AG